{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:53:09Z","timestamp":1769925189536,"version":"3.49.0"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>RPE65<\/jats:italic>\n                    biallelic mutation-associated inherited retinal degeneration (IRD) is currently the only IRD for which gene therapy is approved. This narrative review provides a brief overview of the disease and an update of the current literature on outcomes following the approval of treatment with voretigene neparvovec (LuxturnaTM) in 2017 (USA) and Europe (2018). Post-marketing results confirm a significant therapeutic effect of this gene augmentation on rod function similar to that seen in the phase 1 to 3 clinical trials. The full-field chromatic light sensitivity test is an appropriate test to demonstrate early and sustained effects of treatment. Visual acuity and visual fields may improve in less advanced disease. Accelerated chorioretinal atrophy (CRA) is a previously unrecognised adverse effect that is now reported in 13\u2009% to 50\u2009% of treated eyes. If central, visual acuity loss and paracentral visual field defects may occur. Further studies are needed to identify patients at risk of CRA in order to maximize patient benefit from a costly intervention.\n                  <\/jats:p>","DOI":"10.1515\/medgen-2024-2067","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T08:13:25Z","timestamp":1739261605000},"page":"47-56","source":"Crossref","is-referenced-by-count":4,"title":["Long-term experience with gene augmentation therapy in patients with inherited retinal disease associated with biallelic mutations in\n                    <b>\n                      <i>RPE65<\/i>\n                    <\/b>"],"prefix":"10.1515","volume":"37","author":[{"suffix":"FEBO, FARV","given":"Birgit","family":"Lorenz","sequence":"first","affiliation":[{"name":"c\/o Justus-Liebig-University Giessen TransMIT Centre of Translational Ophthalmology Am Galgenberg 37 Laubach Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2025121816443124023_j_medgen-2024-2067_ref_001","doi-asserted-by":"crossref","unstructured":"Acland GM, Aguirre GD, Bennett J, Aleman TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE, Maguire AM, Palczewski K, Hauswirth WW, Jacobson SG. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther. 2005","DOI":"10.1016\/j.ymthe.2005.08.008"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_002","doi-asserted-by":"crossref","unstructured":"Bommakanti N, Young BK, Sisk RA, Berrocal AM, Duncan JL, Bakall B, Mathias MT, Ahmed I, Chorfi S, Comander J, Nagiel A, Besirli CG. Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration. Ophthalmol Retina. 2024 Jan;8(1):42\u201348. doi: 10.1016\/j.oret.2023.08.017. Epub 2023 Sep 3. PMID: 37660736; PMCID: PMC11138130.","DOI":"10.1016\/j.oret.2023.08.017"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_003","doi-asserted-by":"crossref","unstructured":"Bennett J, Maguire AM. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Cold Spring Harb Perspect Med 2022:a041307. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/36167727\/ [Accessed February 26, 2023].","DOI":"10.1101\/cshperspect.a041307"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_004","doi-asserted-by":"crossref","unstructured":"Bucher K, Rodr\u00edguez-Bocanegra E, Dauletbekov D, Fischer MD. Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 Implications for treatment success and safety. Prog Retin Eye Res 2021;83. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/33069860\/ [Accessed February 26, 2023].","DOI":"10.1016\/j.preteyeres.2020.100915"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_005","doi-asserted-by":"crossref","unstructured":"Cao D, Byrne BJ, de Jong YP, Terhorst C, Duan D, Herzog RW, Kumar SRP. Innate Immune Sensing of Adeno-Associated Virus Vectors. Hum Gene Ther. 2024 Jul;35(13\u201314):451\u2013463. doi: 10.1089\/hum.2024.040. Epub 2024 Jul 5. PMID: 38887999; PMCID: PMC11310564.","DOI":"10.1089\/hum.2024.040"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_006","doi-asserted-by":"crossref","unstructured":"Chung DC, Bertelsen M, Lorenz B, Pennesi ME, Leroy BP, Hamel CP, Pierce E, Sallum J, Larsen M, Stieger K, Preising M, Weleber R, Yang P, Place E, Liu E, Schaefer G, DiStefano-Pappas J, Elci OU, McCague S, Wellman JA, High KA, Reape KZ. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. Am J Ophthalmol. 2019 Mar;199:58\u201370. doi: 10.1016\/j.ajo.2018.09.024. Epub 2018 Sep 28. PMID: 30268864; PMCID: PMC6445969.","DOI":"10.1016\/j.ajo.2018.09.024"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_007","doi-asserted-by":"crossref","unstructured":"Chung DC, McCague S, Yu ZF, Thill S, DiStefano-Pappas J, Bennett J, Cross D, Marshall K, Wellman J, High KA. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 2018 Apr;46(3):247\u2013259. doi: 10.1111\/ceo.13022. Epub 2017 Aug 31. PMID: 28697537; PMCID: PMC5764825.","DOI":"10.1111\/ceo.13022"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_008","doi-asserted-by":"crossref","unstructured":"Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, Kom\u00e1romy AM, Hauswirth WW, Aguirre GD. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):E517\u201325. doi: 10.1073\/pnas.1218933110. Epub 2013 Jan 22. PMID: 23341635; PMCID: PMC3568385.","DOI":"10.1073\/pnas.1218933110"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_009","doi-asserted-by":"crossref","unstructured":"Deng C, Zhao PY, Branham K, Schlegel D, Fahim AT, Jayasundera TK, Khan N, Besirli CG. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis. Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1543\u20131550. doi: 10.1007\/s00417-021-05508-2. Epub 2022 Jan 10. PMID: 35001204; PMCID: PMC9010358.","DOI":"10.1007\/s00417-021-05508-2"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_010","doi-asserted-by":"crossref","unstructured":"Dormegny L, Studer F, Sauer A, Ballonzoli L, Speeg-Schatz C, Bourcier T, Dollfus H, Gaucher D. Could internal limiting membrane peeling before Voretigen neparvovec-ryzl subretinal injection prevent focal chorioretinal atrophy? Heliyon. 2024 Jan 26;10(3):e25154. doi: 10.1016\/j.heliyon.2024.e25154. PMID: 38322949; PMCID: PMC10844059.","DOI":"10.1016\/j.heliyon.2024.e25154"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_011","doi-asserted-by":"crossref","unstructured":"Ducloyer JB, Pichard V, Mevel M, Galy A, Lefevre GM, Brument N, Alvarez-Dorta D, Deniaud D, Mendes-Madeira A, Libeau L, Le Guiner C, Cronin T, Adjali O, Weber M, Le Meur G. Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution. Mol Ther Methods Clin Dev. 2023 Feb 15;28:387\u2013393. doi: 10.1016\/j.omtm.2023.02.006. PMID: 36874242; PMCID: PMC9982454.","DOI":"10.1016\/j.omtm.2023.02.006"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_012","doi-asserted-by":"crossref","unstructured":"Fischer MD, Simonelli F, Sahni J, Holz FG, Maier R, Fasser C, Suhner A, Stiehl DP, Chen B, Audo I, Leroy BP; PERCEIVE Study Group. Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study. Biomolecules. 2024 Jan 17;14(1):122. doi: 10.3390\/biom14010122. PMID: 38254722; PMCID: PMC10813228.","DOI":"10.3390\/biom14010122"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_013","doi-asserted-by":"crossref","unstructured":"Gange WS, Sisk RA, Besirli CG, et al. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis. Ophthalmol Retina 2022;6:58\u201364. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/33838313\/ [Accessed February 26, 2023].","DOI":"10.1016\/j.oret.2021.03.016"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_014","doi-asserted-by":"crossref","unstructured":"Gerhardt MJ, Priglinger CS, Rudolph G, et al. Gene Therapy with Voretigene Neparvovec Improves Vision and Partially Restores Electrophysiological Function in Pre-School Children with Leber Congenital Amaurosis. Biomedicines 2022;11. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/36672611\/ [Accessed February 26, 2023].","DOI":"10.3390\/biomedicines11010103"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_015","doi-asserted-by":"crossref","unstructured":"Hull S, Holder GE, Robson AG, Mukherjee R, Michaelides M, Webster AR, Moore AT. Preserved visual function in retinal dystrophy due to hypomorphic RPE65 mutations. Br J Ophthalmol. 2016 Nov;100(11):1499\u20131505. doi: 10.1136\/bjophthalmol-2015-308019. Epub 2016 Feb 23. PMID: 26906952.","DOI":"10.1136\/bjophthalmol-2015-308019"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_016","doi-asserted-by":"crossref","unstructured":"Jacobson SG, Cideciyan AV, Ratnakaram R, Heon E, Schwartz SB, Roman AJ, Peden MC, Aleman TS, Boye SL, Sumaroka A, Conlon TJ, Calcedo R, Pang JJ, Erger KE, Olivares MB, Mullins CL, Swider M, Kaushal S, Feuer WJ, Iannaccone A, Fishman GA, Stone EM, Byrne BJ, Hauswirth WW. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012 Jan;130(1):9\u201324. doi: 10.1001\/archophthalmol.2011.298. Epub 2011 Sep 12. PMID: 21911650; PMCID: PMC3600816.","DOI":"10.1001\/archophthalmol.2011.298"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_017","doi-asserted-by":"crossref","unstructured":"Johnson S, Buessing M, O\u2019Connell T, et al. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease. JAMA Ophthalmol 2019;137:1115\u20131123. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/31318398\/ [Accessed February 26, 2023]","DOI":"10.1001\/jamaophthalmol.2019.2512"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_018","doi-asserted-by":"crossref","unstructured":"Kessel L, Christensen UC, Klemp K. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy. Ophthalmology 2022;129:1287\u20131293. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/35760216\/ [Accessed February 26, 2023].","DOI":"10.1016\/j.ophtha.2022.06.018"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_019","doi-asserted-by":"crossref","unstructured":"Kiraly P, Cottriall CL, Taylor LJ, Jolly JK, Cehajic-Kapetanovic J, Yusuf IH, Martinez-Fernandez de la Camara C, Shanks M, Downes SM, MacLaren RE, Fischer MD. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic RPE65-Mediated Inherited Retinal Dystrophies in a Cohort of Patients from a Single Center. Biomolecules. 2023 Oct 5;13(10):1484. doi: 10.3390\/biom13101484. PMID: 37892166; PMCID: PMC10605275.","DOI":"10.3390\/biom13101484"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_020","doi-asserted-by":"crossref","unstructured":"Ku CA, Igelman AD, Huang SJ, Vasconcelos H, da Palma MM, Bailey ST, Lauer AK, Weleber RG, Yang P, Pennesi ME. Improved Rod Sensitivity as Assessed by Two-Color Dark-Adapted Perimetry in Patients With RPE65-Related Retinopathy Treated With Voretigene Neparvovec-rzyl. Transl Vis Sci Technol. 2023 Apr 3;12(4):17. doi: 10.1167\/tvst.12.4.17. PMID: 37058101; PMCID: PMC10117223.","DOI":"10.1167\/tvst.12.4.17"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_021","doi-asserted-by":"crossref","unstructured":"K\u00fcnzel SH, Mahren E, Morr M, Holz FG, Lorenz B; Arbeitsgruppe IRDs in Deutschland. Diagnostik und Management von Patient*innen mit erblichen Netzhautdegenerationen in Deutschland: Ergebnisse einer bundesweiten Umfrage an universit\u00e4ren und nichtuniversit\u00e4ren Augenkliniken sowie Schwerpunktpraxen. [Diagnostics and management of patients with inherited retinal diseases in Germany: Results of a nationwide survey of university and non-university eye departments and specialized practices] Ophthalmologie. 2023 Nov;120(11):1127\u20131137. German. doi: 10.1007\/s00347-023-01902-9. Epub 2023 Aug 15. PMID: 37582888","DOI":"10.1007\/s00347-023-01902-9"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_022","doi-asserted-by":"crossref","unstructured":"Kumaran N, Moore AT, Weleber RG, Michaelides M. Leber congenital amaurosis\/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Br J Ophthalmol. 2017 Sep;101(9):1147\u20131154. doi: 10.1136\/bjophthalmol-2016-309975. Epub 2017 Jul 8. Erratum in: Br J Ophthalmol. 2019 Jun;103(6):862. doi: 10.1136\/bjophthalmol-2016-309975corr1. PMID: 28689169; PMCID: PMC5574398.","DOI":"10.1136\/bjophthalmol-2016-309975"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_023","doi-asserted-by":"crossref","unstructured":"Kumaran N, Georgiou M, Bainbridge JWB, Bertelsen M, Larsen M, Blanco-Kelly F, Ayuso C, Tran HV, Munier FL, Kalitzeos A, Michaelides M. Retinal Structure in RPE65-Associated Retinal Dystrophy. Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):47. doi: 10.1167\/iovs.61.4.47. PMID: 32347917; PMCID: PMC7401957.","DOI":"10.1167\/iovs.61.4.47"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_024","doi-asserted-by":"crossref","unstructured":"Leroy BP, Fischer MD, Flannery JG, MacLaren RE, Dalkara D, Scholl HPN, Chung DC, Spera C, Viriato D, Banhazi J. Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect. Ophthalmic Res. 2023;66(1):179\u2013196. doi: 10.1159\/000526317. Epub 2022 Sep 14. PMID: 36103843.","DOI":"10.1159\/000526317"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_025","doi-asserted-by":"crossref","unstructured":"Lopez J, Borchert M, Lee TC, Nagiel A. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy. Br J Ophthalmol 2023;107. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/35835501\/ [Accessed February 26, 2023].","DOI":"10.1136\/bjo-2022-321488"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_026","doi-asserted-by":"crossref","unstructured":"Lorenz B, K\u00fcnzel SH, Preising MN, Scholz JP, Chang P, Holz FG, Herrmann P. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting. Ophthalmology. 2024 Feb;131(2):161\u2013178. doi: 10.1016\/j.ophtha.2023.09.006. Epub 2023 Sep 12. Erratum in: Ophthalmology. 2024 Apr 11:S0161-6420(24)00160-X. doi: 10.1016\/j.ophtha.2024.02.021. PMID: 37704110.","DOI":"10.1016\/j.ophtha.2023.09.006"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_027","doi-asserted-by":"crossref","unstructured":"Lorenz B, Tavares J, van den Born LI, Marques JP, Pilotto E, Stingl K, Charbel Issa P, Leroux D, Dollfus H, Scholl HPN. Current Management of Patients with RPE65 Mutation Associated Inherited Retinal Degenerations in Europe: Results of a 2-Year Follow-Up Multinational Survey. Ophthalmic Res. 2023;66(1):727\u2013748. doi: 10.1159\/000529777. Epub 2023 Mar 6. PMID: 36878196.","DOI":"10.1159\/000529777"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_028","doi-asserted-by":"crossref","unstructured":"Lorenz B, Poliakov E, Schambeck M, Friedburg C, Preising MN, Redmond TM. A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation. Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5235\u201342. doi: 10.1167\/iovs.07-1671. Epub 2008 Jul 3. PMID: 18599565; PMCID: PMC5015590.","DOI":"10.1167\/iovs.07-1671"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_029","doi-asserted-by":"crossref","unstructured":"Lorenz B, Wabbels B, Wegscheider E, Hamel CP, Drexler W, Preising MN. Lack of fundus autofluorescence to 488 nanometers from childhood on in patients with early-onset severe retinal dystrophy associated with mutations in RPE65. Ophthalmology. 2004 Aug;111(8):1585\u201394. doi: 10.1016\/j.ophtha.2004.01.033. PMID: 15288992.","DOI":"10.1016\/j.ophtha.2004.01.033"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_030","unstructured":"Lorenz B, Gy\u00fcr\u00fcs P, Preising M, Bremser D, Gu S, Andrassi M, Gerth C, Gal A. Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2735\u201342. PMID: 10937591."},{"key":"2025121816443124023_j_medgen-2024-2067_ref_031","doi-asserted-by":"crossref","unstructured":"Maguire AM, Russell S, Chung DC, et al. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. Ophthalmology. 2021;128(10):1460\u20131468. doi:10.1016\/j.ophtha.2021.03.031","DOI":"10.1016\/j.ophtha.2021.03.031"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_032","doi-asserted-by":"crossref","unstructured":"Melillo P, Testa F, Di Iorio V, Karali M, Citro A, Della Corte M, Rossi S, Banfi S, Simonelli F. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice. Ophthalmol Retina. 2024 Jul;8(7):688\u2013698. doi: 10.1016\/j.oret.2024.01.021. Epub 2024 Feb 1. PMID: 38295874.","DOI":"10.1016\/j.oret.2024.01.021"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_033","doi-asserted-by":"crossref","unstructured":"Paunescu K, Wabbels B, Preising MN, Lorenz B. Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol. 2005;243(5):417\u2013426. doi:10.1007\/s00417-004-1020-x","DOI":"10.1007\/s00417-004-1020-x"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_034","doi-asserted-by":"crossref","unstructured":"Pennesi ME, Weleber RG, Yang P, Whitebirch C, Thean B, Flotte TR, Humphries M, Chegarnov E, Beasley KN, Stout JT, Chulay JD. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy. Hum Gene Ther. 2018 Dec;29(12):1428\u20131437. doi: 10.1089\/hum.2018.014. Epub 2018 Jul 24. PMID: 29869534","DOI":"10.1089\/hum.2018.014"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_035","doi-asserted-by":"crossref","unstructured":"Redmond TM, Poliakov E, Yu S, et al. Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci U S A 2005;102:13658\u201313663. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/16150724\/ [Accessed March 17, 2023].","DOI":"10.1073\/pnas.0504167102"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_036","doi-asserted-by":"crossref","unstructured":"Reichel FF, Seitz I, Wozar F, et al. Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec. Br J Ophthalmol 2022. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/35609955\/ [Accessed February 26, 2023].","DOI":"10.1136\/bjophthalmol-2021-321023"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_037","doi-asserted-by":"crossref","unstructured":"Roman AJ, Cideciyan A v., Schwartz SB, et al. Intervisit variability of visual parameters in Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 2013;54:1378\u20131383. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/23341016\/ [Accessed February 26, 2023].","DOI":"10.1167\/iovs.12-11341"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_038","doi-asserted-by":"crossref","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017 Aug 26;390(10097):849\u2013860. doi: 10.1016\/S0140-6736(17)31868-8. Epub 2017 Jul 14. Erratum in: Lancet. 2017 Aug 26;390(10097):848. PMID: 28712537; PMCID: PMC5726391.","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_039","doi-asserted-by":"crossref","unstructured":"Sallum JMF, Kaur VP, Shaikh J, Banhazi J, Spera C, Aouadj C, Viriato D, Fischer MD. Epidemiology of Mutations in the 65-kDa Retinal Pigment Epithelium (RPE65) Gene-Mediated Inherited Retinal Dystrophies: A Systematic Literature Review. Adv Ther. 2022 Mar;39(3):1179\u20131198. doi: 10.1007\/s12325-021-02036-7. Epub 2022 Jan 30. PMID: 35098484; PMCID: PMC8918161.","DOI":"10.1007\/s12325-021-02036-7"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_040","doi-asserted-by":"crossref","unstructured":"Sengillo JD, Gregori NZ, Sisk RA, et al. Visual Acuity, Retinal Morphology, and Patients\u2019 Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease. Ophthalmol Retina 2022;6:273\u2013283. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/34896323\/ [Accessed February 26, 2023].","DOI":"10.1016\/j.oret.2021.11.005"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_041","doi-asserted-by":"crossref","unstructured":"Stingl K, Kempf M, Bartz-Schmidt KU, Dimopoulos S, Reichel F, Jung R, Kelbsch C, Kohl S, Kort\u00fcm FC, Nasser F, Peters T, Wilhelm B, Wissinger B, Wozar F, Zrenner E, Fischer MD, Stingl K. Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec. Br J Ophthalmol. 2022 Jun;106(6):831\u2013838. doi: 10.1136\/bjophthalmol-2020-318286. Epub 2021 Jan 20. PMID: 33472769; PMCID: PMC9132865.","DOI":"10.1136\/bjophthalmol-2020-318286"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_042","doi-asserted-by":"crossref","unstructured":"Stingl K, Stingl K, Schwartz H, et al. Full-field scotopic threshold improvement following voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy. Ophthalmology 2023. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/36822437\/ [Accessed February 26, 2023].","DOI":"10.1016\/j.ophtha.2023.02.015"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_043","doi-asserted-by":"crossref","unstructured":"Testa F, Murro V, Signorini S, Colombo L, Iarossi G, Parmeggiani F, Falsini B, Salvetti AP, Brunetti-Pierri R, Aprile G, Bertone C, Suppiej A, Romano F, Karali M, Donati S, Melillo P, Sodi A, Quaranta L, Rossetti L, Buzzonetti L, Chizzolini M, Rizzo S, Staurenghi G, Banfi S, Azzolini C, Simonelli F. RPE65-Associated Retinopathies in the Italian Population: A Longitudinal Natural History Study. Invest Ophthalmol Vis Sci. 2022a Feb 1;63(2):13. doi: 10.1167\/iovs.63.2.13. PMID: 35129589; PMCID: PMC8822366","DOI":"10.1167\/iovs.63.2.13"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_044","doi-asserted-by":"crossref","unstructured":"Testa F, Melillo P, Di Iorio V, Iovino C, Farinaro F, Karali M, Banfi S, Rossi S, Della Corte M, Simonelli F. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy. Sci Rep. 2022b Oct 21;12(1):17637. doi: 10.1038\/s41598-022-22180-6. PMID: 36271235; PMCID: PMC9586929.","DOI":"10.1038\/s41598-022-22180-6"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_045","doi-asserted-by":"crossref","unstructured":"Testa F, Bacci G, Falsini B, Iarossi G, Melillo P, Mucciolo DP, Murro V, Salvetti AP, Sodi A, Staurenghi G, Simonelli F. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Eye (Lond). 2024 Sep;38(13):2504\u20132515. doi: 10.1038\/s41433-024-03065-6. Epub 2024 Apr 16. PMID: 38627549; PMCID: PMC11385234.","DOI":"10.1038\/s41433-024-03065-6"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_046","doi-asserted-by":"crossref","unstructured":"Uhrmann MF, Lorenz B, Gissel C. Cost Effectiveness of Voretigene Neparvovec for RPE65-Mediated Inherited Retinal Degeneration in Germany. Transl Vis Sci Technol 2020;9:1\u20138. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/32879773\/ [Accessed February 26, 2023]","DOI":"10.1167\/tvst.9.9.17"},{"key":"2025121816443124023_j_medgen-2024-2067_ref_047","doi-asserted-by":"crossref","unstructured":"Walsh N, Cooper A, Dockery A, O\u2019Byrne JJ. Variant reclassification and clinical implications. J Med Genet. 2024 Feb 21;61(3):207\u2013211. doi: 10.1136\/jmg-2023-109488. PMID: 38296635.","DOI":"10.1136\/jmg-2023-109488"}],"container-title":["Medizinische Genetik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2024-2067\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2024-2067\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:55:07Z","timestamp":1766076907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2024-2067\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,2,6]]}},"alternative-id":["10.1515\/medgen-2024-2067"],"URL":"https:\/\/doi.org\/10.1515\/medgen-2024-2067","relation":{},"ISSN":["1863-5490","0936-5931"],"issn-type":[{"value":"1863-5490","type":"electronic"},{"value":"0936-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}